Vifor Pharma AG (LTS:0RPD) Cash-to-Debt : 1.69 (As of Dec. 2021)

View and export this data going back to 2014. Start your Free Trial

What is Vifor Pharma AG Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Vifor Pharma AG's cash to debt ratio for the quarter that ended in Dec. 2021 was 1.69.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Vifor Pharma AG could pay off its debt using the cash in hand for the quarter that ended in Dec. 2021.

The historical rank and industry rank for Vifor Pharma AG's Cash-to-Debt or its related term are showing as below:

LTS:0RPD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09 Med: 0.69 Max: No Debt
Current: 1.69

During the past 13 years, Vifor Pharma AG's highest Cash to Debt Ratio was No Debt. The lowest was 0.09. And the median was 0.69.

LTS:0RPD's Cash-to-Debt is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.94 vs LTS:0RPD: 1.69

Vifor Pharma AG Cash-to-Debt Historical Data

The historical data trend for Vifor Pharma AG's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Vifor Pharma AG Cash-to-Debt Chart

Vifor Pharma AG Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Cash-to-Debt

Get a 7-Day Free Trial

2.16

0.71

0.89

1.21

1.69

Vifor Pharma AG Semi-Annual Data
	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21
Cash-to-Debt	Get a 7-Day Free Trial															0.89	4.38	1.21	11.25	1.69

Competitive Comparison of Vifor Pharma AG's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Vifor Pharma AG's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vifor Pharma AG's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vifor Pharma AG's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Vifor Pharma AG's Cash-to-Debt falls into.

Vifor Pharma AG Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Vifor Pharma AG's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	993.6	/	(477	+	110.1)
	=	1.69

Vifor Pharma AG's Cash to Debt Ratio for the quarter that ended in Dec. 2021 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	993.6	/	(477	+	110.1)
	=	1.69

Vifor Pharma AG (LTS:0RPD) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Vifor Pharma AG Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Vifor Pharma AG's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Vifor Pharma AG (LTS:0RPD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vifor Pharma AG (LTS:0RPD) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Rechenstrasse 37, Saint Gallen, CHE, 9014

Website

https://www.viforpharma.com

Vifor Pharma AG is a specialty drug manufacturing and licensing company. It researches, develops, and produces its pharmaceutical products and markets and distributes them worldwide. Most of its sales are generated in the USA, with Europe also a strong contributor. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Vifor Pharma AG (LTS:0RPD) Headlines

No Headlines